Incidence and association of high-risk HPVs and EBV in patients with advanced stages of colorectal cancer from Qatar
High-risk Human Papillomaviruses (HPVs) and Epstein – Barr virus (EBV) are present and involved in several types of human carcinomas, including cervical and, head and neck cancers. Nevertheless, their presence and association in the pathogenesis of colorectal cancer is still nascent. The current study explored the association between the high-risk HPVs and EBV and tumor phenotype in colorectal cancers (CRCs) in the Qatari population. We found that high-risk HPVs and EBV are present in 69/100 and 21/100 cases, respectively. Additionally, 17% of the cases showed a copresence of high-risk HPVs and EBV, with a significant correlation only between the HPV45 subtype and EBV (p = .004). While the copresence did not significantly associate with clinicopathological characteristics, we identified that coinfection with more than two subtypes of HPV is a strong predictor of advanced stage CRC, and the confounding effect of the copresence of EBV in such cases strengthens this association. Our results indicate that high-risk HPVs and EBV can co-present in human CRCs in the Qatari population where they could plausibly play a specific role in human colorectal carcinogenesis. However, future studies are essential to confirm their copresence and synergistic role in developing CRCs.
Other Information
Published in: Human Vaccines & Immunotherapeutics
License: http://creativecommons.org/licenses/by-nc-nd/4.0/
See article on publisher's website: https://dx.doi.org/10.1080/21645515.2023.2220626
Funding
Open Access funding provided by the Qatar National Library.
History
Language
- English
Publisher
Taylor & FrancisPublication Year
- 2023
License statement
This Item is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.Institution affiliated with
- Qatar University
- Biomedical Research Center - QU
- Qatar University Health - QU
- College of Medicine - QU HEALTH
- Hamad Medical Corporation
- National Center for Cancer Care and Research - HMC